Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Offers Invader to Japanese Cancer Center

NEW YORK, April 2 - Japan's National Cancer Center will use Third Wave's Invader technology to genotype more than 100,000 genetic variations among several hundred individuals in a study to better understand the genetic foundations of cancer.


Terms of the agreement call for Third Wave to provide the NCC with access to the Invader system as well as undisclosed "collaborative support" for the study. In return, Third Wave will receive an initial multi-million dollar payment from the cancer center as well as follow-on product sales and the ability to license any discoveries that arise from the study.

Other financial details were not released.

The NCC was established in 1962 as the only national government-supported cancer center in Japan. It comprises two research facilities and two hospitals that serve more than 500,000 cancer patients each year, according to the NCC.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.